CA2269780C - Polyanionic polymers as adjuvants for mucosal immunization - Google Patents

Polyanionic polymers as adjuvants for mucosal immunization Download PDF

Info

Publication number
CA2269780C
CA2269780C CA002269780A CA2269780A CA2269780C CA 2269780 C CA2269780 C CA 2269780C CA 002269780 A CA002269780 A CA 002269780A CA 2269780 A CA2269780 A CA 2269780A CA 2269780 C CA2269780 C CA 2269780C
Authority
CA
Canada
Prior art keywords
adjuvant
acid
paa
specimens
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002269780A
Other languages
English (en)
French (fr)
Other versions
CA2269780A1 (en
Inventor
Luuk Hilgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Schweiz GmbH
Original Assignee
Dimminaco AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimminaco AG filed Critical Dimminaco AG
Publication of CA2269780A1 publication Critical patent/CA2269780A1/en
Application granted granted Critical
Publication of CA2269780C publication Critical patent/CA2269780C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
CA002269780A 1996-10-24 1997-10-23 Polyanionic polymers as adjuvants for mucosal immunization Expired - Lifetime CA2269780C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9622159.3 1996-10-24
GBGB9622159.3A GB9622159D0 (en) 1996-10-24 1996-10-24 Polyanionic polymers as adjuvants for mucosal immunization
PCT/EP1997/005861 WO1998017310A2 (en) 1996-10-24 1997-10-23 Polyanionic polymers as adjuvants for mucosal immunization

Publications (2)

Publication Number Publication Date
CA2269780A1 CA2269780A1 (en) 1998-04-30
CA2269780C true CA2269780C (en) 2008-12-02

Family

ID=10801896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002269780A Expired - Lifetime CA2269780C (en) 1996-10-24 1997-10-23 Polyanionic polymers as adjuvants for mucosal immunization

Country Status (11)

Country Link
US (1) US6610310B2 (enExample)
EP (1) EP0934077B1 (enExample)
JP (1) JP4344014B2 (enExample)
AT (1) ATE360440T1 (enExample)
AU (1) AU717349B2 (enExample)
BR (1) BR9712436A (enExample)
CA (1) CA2269780C (enExample)
DE (1) DE69737658T2 (enExample)
ES (1) ES2285741T3 (enExample)
GB (1) GB9622159D0 (enExample)
WO (1) WO1998017310A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20050129680A1 (en) * 2001-09-17 2005-06-16 Paul Wentworth Antimicrobial activity of antibodies
US20040157280A1 (en) * 2001-09-17 2004-08-12 Paul Wentworth Antibody mediated ozone generation
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2004044582A2 (en) * 2002-11-14 2004-05-27 Novartis Ag Antibody- or neutrophil-mediated ozone generation
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
JP4860109B2 (ja) * 2003-12-26 2012-01-25 バイオリーダース・コーポレイション ポリガンマグルタミン酸を含む免疫増強用組成物
DE102006047617B4 (de) * 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
FR2922767B1 (fr) * 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
ME01000B (me) 2007-11-06 2012-10-20 Zoetis Services Llc Živa vakcina avirulentne mycoplasma hyopneumoniae sa adjuvansom
EP2062594A1 (en) * 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
DE102008017216B4 (de) * 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition
GB0907989D0 (en) 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
US20130310462A1 (en) 2010-08-04 2013-11-21 Tixupharma Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
PT2654784T (pt) 2010-12-22 2017-02-13 Wyeth Llc Composições imunogénicas estáveis de antigénios de staphylococcus aureus
DE102010056564A1 (de) 2010-12-30 2012-07-05 Clariant International Limited Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
DE102010056566A1 (de) * 2010-12-30 2012-07-05 Clariant International Ltd. Kontinuierliches Verfahren zur Veresterung Säuregruppen tragender Polymere
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US8986710B2 (en) 2012-03-09 2015-03-24 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CN104870463B (zh) 2012-12-20 2018-09-28 辉瑞公司 糖缀合方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2662685C2 (ru) 2013-09-25 2018-07-26 Зоэтис Сервисиз Ллс Pcv2b дивергентная вакцинная композиция и способы её применения
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
IL255106B2 (en) 2015-05-04 2023-04-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
HRP20250077T1 (hr) * 2016-06-17 2025-03-28 Boehringer Ingelheim Vetmedica Gmbh Nove imunogene formulacije koje sadrže ravne ili razgranate polimerne adjuvante poliakrilne kiseline
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
JP7497293B2 (ja) 2018-03-16 2024-06-10 ゾエティス・サービシーズ・エルエルシー インターロイキン－３１に対するペプチドワクチン
CN109134724A (zh) * 2018-07-24 2019-01-04 石家庄哈顿生物技术有限公司 一种动物疫苗用聚丙烯酸类聚合物佐剂的研制方法
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP2023538736A (ja) 2020-08-26 2023-09-11 ファイザー・インク Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
ES2052685T3 (es) * 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
EP0532833A1 (en) * 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.

Also Published As

Publication number Publication date
WO1998017310A2 (en) 1998-04-30
BR9712436A (pt) 2000-10-24
JP2001507336A (ja) 2001-06-05
DE69737658T2 (de) 2008-01-31
EP0934077B1 (en) 2007-04-25
AU717349B2 (en) 2000-03-23
EP0934077A2 (en) 1999-08-11
CA2269780A1 (en) 1998-04-30
ATE360440T1 (de) 2007-05-15
AU5313398A (en) 1998-05-15
GB9622159D0 (en) 1996-12-18
JP4344014B2 (ja) 2009-10-14
WO1998017310A3 (en) 1998-06-18
US6610310B2 (en) 2003-08-26
US20030021793A1 (en) 2003-01-30
ES2285741T3 (es) 2007-11-16
DE69737658D1 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
CA2269780C (en) Polyanionic polymers as adjuvants for mucosal immunization
US6511677B1 (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6287604B1 (en) Biodegradable targetable microparticle delivery system
EP0762875B1 (en) Microparticle delivery system
JP2001526640A (ja) モノホスホリルリピドａの水性免疫アジュバント組成物
Jain et al. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization
JPH10501568A (ja) 抗ウイルス性デンドリマー
KR20100138850A (ko) 폴리감마글루탐산-키토산 나노입자를 함유하는 면역보강제 조성물
JP3365635B2 (ja) キトサン誘導性免疫強化
JPH09500132A (ja) ヒドロゲルマイクロカプセル化ワクチン
JP2002537351A (ja) コーロバクターリポ多糖免疫アジュバント
MXPA99003830A (en) Polyanionic polymers as adjuvants for mucosal immunization
JPH11502191A (ja) ワクチンアジュバント
JP2002504521A (ja) 粘膜の微粒子共役ワクチン
JP4095696B2 (ja) 鳥類腸管リンパ組織への取込目的物搬送用の微粒子及び搬送方法
WO2000076476A1 (en) Adjuvant-containing polymerized liposomes for oral, mucosal or intranasal vaccination
CN115920027A (zh) 纳米疫苗佐剂及其在制备提高石斛多糖释放力药物上的应用
Liao et al. Carbopol Dispersed U@ PAA with High Colloidal Stability as a Combination Nano-Adjuvant Boosts Immune Responses and Protection Against Pseudorabies Virus in Mice and Pigs
MXPA00006531A (en) Novel polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
MXPA97004823A (en) Adjuvants for vacu

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20171023